3 Richly Valued Stocks I'll Be Watching Like a Hawk in 2025

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and with caution. Today, the market's average price-to-earnings (P/E) multiple is around 30.6. So stocks with P/E ratios that are higher than that might be a bit overvalued -- or perhaps opportunities to pay a premium for a high-quality investment.This year, I'm going to be particularly watching three companies with valuations on the higher side, and you might want to as well. Even if you don't buy them, they're probably worth tracking. Here's why.As the creator of the blockbuster weight-loss drug Zepbound, and the blockbuster type 2 diabetes drug Mounjaro, Eli Lilly (NYSE: LLY) is exposed to a tremendous amount of opportunity. But with a P/E of 79, few would call its shares a bargain.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool